Brookline Capital Management Comments on KYMR Q3 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Equities researchers at Brookline Capital Management lifted their Q3 2025 earnings per share (EPS) estimates for shares of Kymera Therapeutics in a report released on Monday, July 7th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings per share of ($0.92) for the quarter, up from their previous estimate of ($1.03). The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. Brookline Capital Management also issued estimates for Kymera Therapeutics' Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($3.03) EPS, FY2026 earnings at ($4.29) EPS, FY2027 earnings at ($4.74) EPS, FY2028 earnings at ($5.68) EPS and FY2029 earnings at ($5.11) EPS.

Other equities research analysts have also issued research reports about the company. HC Wainwright reissued a "buy" rating and issued a $60.00 price objective (up previously from $54.00) on shares of Kymera Therapeutics in a report on Thursday, June 26th. Bank of America raised Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price objective for the company in a report on Monday, June 2nd. Oppenheimer reaffirmed an "outperform" rating and set a $53.00 target price (down previously from $56.00) on shares of Kymera Therapeutics in a report on Friday, June 27th. UBS Group reduced their target price on Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Finally, Wells Fargo & Company reduced their target price on Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating for the company in a report on Thursday, June 26th. Two equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $59.11.

Kymera Therapeutics Stock Down 1.6%

KYMR traded down $0.73 during trading hours on Wednesday, hitting $44.48. The stock had a trading volume of 596,846 shares, compared to its average volume of 622,396. The company's fifty day simple moving average is $39.47 and its 200 day simple moving average is $36.04. Kymera Therapeutics has a 1 year low of $19.45 and a 1 year high of $53.27. The stock has a market cap of $2.90 billion, a PE ratio of -14.35 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.10. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The company had revenue of $22.10 million during the quarter, compared to analyst estimates of $11.38 million. During the same quarter last year, the firm posted ($0.69) EPS. The firm's revenue for the quarter was up 114.6% on a year-over-year basis.

Insider Activity at Kymera Therapeutics

In other news, Director Bros. Advisors Lp Baker bought 655,500 shares of the company's stock in a transaction that occurred on Monday, June 30th. The stock was bought at an average price of $44.00 per share, for a total transaction of $28,842,000.00. Following the transaction, the director directly owned 6,117,295 shares of the company's stock, valued at $269,160,980. This represents a 12.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey W. Albers sold 6,349 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $311,101.00. The disclosure for this sale can be found here. Insiders have sold 48,349 shares of company stock valued at $2,334,301 in the last ninety days. Insiders own 16.01% of the company's stock.

Institutional Trading of Kymera Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its position in Kymera Therapeutics by 3.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,870,333 shares of the company's stock worth $276,395,000 after buying an additional 224,859 shares during the last quarter. Wellington Management Group LLP lifted its position in Kymera Therapeutics by 13.0% in the 1st quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company's stock worth $164,134,000 after buying an additional 689,547 shares during the last quarter. Vanguard Group Inc. lifted its position in Kymera Therapeutics by 7.0% in the 1st quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company's stock worth $143,183,000 after buying an additional 344,080 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in Kymera Therapeutics by 14.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock worth $207,184,000 after buying an additional 650,000 shares during the last quarter. Finally, Siren L.L.C. lifted its position in Kymera Therapeutics by 9.1% in the 1st quarter. Siren L.L.C. now owns 3,240,313 shares of the company's stock worth $88,687,000 after buying an additional 270,580 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.